TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1538159

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine (40 micrograms, three doses on days 0, 30, and 180)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sera from HIV-1 antibody-negative volunteers (before vaccination)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sera from vaccinated volunteers (after vaccination)
Number of subjects: 17
Study: 6337801

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (SR-OX) once daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: Oxprenolol (OX) twice daily
Number of subjects: 178
Study: 31118469

Group type: EXPERIMENTAL
Intervention: Physical colour stimuli reflecting human perceptual constraints on colours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised stimuli that distort perceptual constraints
Number of subjects: 0
Study: 29095706

Group type: EXPERIMENTAL
Intervention: 12 weeks of exercise and falls prevention education
Number of subjects: 24

Group type: COMPARATOR
Intervention: Falls prevention education only
Number of subjects: 24
Study: 26701163

Group type: EXPERIMENTAL
Intervention: Video/computer‐based interactive exercises for 1 hour on weekdays, mainly involving stepping and weight‐shifting exercises.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Video/computer‐based interactive exercises.
Number of subjects: 58
Study: 24700145

Group type: EXPERIMENTAL
Intervention: High-variability condition (24 unique verbs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-variability condition (12 unique verbs)
Number of subjects: 18
Study: 22844025

Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 20491770

Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 10% ALA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 15% ALA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 20% ALA
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo agent (control)
Number of subjects: 180
Study: 18614736

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg Zn + 60 mg Fe + 250 microg folic acid)
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Control (60 mg Fe + 250 microg folic acid)
Number of subjects: 1295

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1295
Study: 16094739

Group type: EXPERIMENTAL
Intervention: Immediate thoracic radiotherapy (TRT)
Number of subjects: 407
Study: 11956673

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (1 liter daily for 3 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 24
Study: 10066994

Group type: EXPERIMENTAL
Intervention: Auditory backward masking in schizophrenic participants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Auditory backward masking in controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No-mask performance in schizophrenic participants
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-mask performance in controls
Number of subjects: 30
Study: 7726447

Group type: EXPERIMENTAL
Intervention: Diet + 250 mg acipimox (a nicotinic acid compound) two to three times/day
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nonrandomized group (reference population)
Number of subjects: 85
Study: 31220365

Group type: EXPERIMENTAL
Intervention: Screening and treatment for fracture risk
Number of subjects: 11032
Study: 29616481

Group type: EXPERIMENTAL
Intervention: Yoga breathing (YB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard breathing
Number of subjects: 32
Study: 27315267

Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 25377966

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) used for the repair of ear drum perforation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 32
Study: 22504100

Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the floor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-finger technique on the floor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the table
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-finger technique on the table
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the radiant warmer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-finger technique on the radiant warmer
Number of subjects: 20
Study: 19652068

Group type: EXPERIMENTAL
Intervention: Bendamustine 100 mg/m²/day intravenously on days 1 to 2, repeated every 4 weeks for a maximum of six cycles.
Number of subjects: 319

Group type: COMPARATOR
Intervention: Chlorambucil 0.8 mg/kg orally on days 1 and 15, repeated every 4 weeks for a maximum of six cycles.
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 319
Study: 17118682

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 118
Study: 15036825

Group type: EXPERIMENTAL
Intervention: FBG monitoring group with titration target 4.4-6.1 mmol/l
Number of subjects: 385

Group type: COMPARATOR
Intervention: PPBG monitoring group with titration target 4.4-8.0 mmol/l
Number of subjects: 385
Study: 11197251

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10920943

Group type: EXPERIMENTAL
Intervention: Leucomax (rhGM-CSF)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Combination chemotherapy alone
Number of subjects: 57
Study: 8305998

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Intranasal spray
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 17703

Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 17703
Study: 2543492

Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both CPN and PPN
Number of subjects: 24
Study: 1101843

Group type: EXPERIMENTAL
Intervention: Perphenazine, 20 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amitriptyline-perphenazine, 20 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride, 125 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 31209560

Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (10,000 IU/dose; n=98)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (n=98)
Number of subjects: 196
Study: 28506228

Group type: EXPERIMENTAL
Intervention: Pulian ointment
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 294
Study: 26173573

Group type: EXPERIMENTAL
Intervention: Video modeling (VM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-based instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 0
Study: 23468338

Group type: EXPERIMENTAL
Intervention: Ramp incremental test
Number of subjects: 13

Group type: COMPARATOR
Intervention: Step incremental test
Number of subjects: 13
Study: 21518005

Group type: EXPERIMENTAL
Intervention: Freshly derived dental pulp tissues (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (liq N(2))-stored dental pulp tissues (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Liquid nitrogen (liq N(2))-stored intact teeth (Group C)
Number of subjects: 50
Study: 18505369

Group type: EXPERIMENTAL
Intervention: Teriparatide for 24 months
Number of subjects: 503
Study: 16566731

Group type: EXPERIMENTAL
Intervention: 5-ALA-PDT plus 3% azone
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5-ALA-PDT alone
Number of subjects: 36
Study: 12656905

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cinnoxicam (30 mg suppository every 4 days for 12 months)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (glycerine suppository every 4 days for 12 months)
Number of subjects: 156
Study: 11078249

Group type: EXPERIMENTAL
Intervention: 8-mm split-tip ablation catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4-mm tip ablation catheter
Number of subjects: 30
Study: 8625641

Group type: EXPERIMENTAL
Intervention: Availability of daily itemized patient charges during the intervention period
Number of subjects: 598

Group type: COMPARATOR
Intervention: Control group (no availability of daily itemized patient charges)
Number of subjects: 598
Study: 1290473

Group type: EXPERIMENTAL
Intervention: Intraperitoneal insemination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Timed intercourse (control)
Number of subjects: 26
Study: 6377610

Group type: EXPERIMENTAL
Intervention: HLA-A+B matching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-DR matching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other factors (blood transfusion, preformed antibodies, graft number, recipient sex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-B+DR matching
Number of subjects: 0
Study: 28858971

Group type: EXPERIMENTAL
Intervention: Family-based training program for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 27103767

Group type: EXPERIMENTAL
Intervention: HealthKick intervention
Number of subjects: 998
Study: 25072976

Group type: EXPERIMENTAL
Intervention: Early pressure dressing (elastic bandage or general wrapping) applied 7 to 10 days after DC
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control treatment (general wrapping)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Early pressure dressing
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 169
Study: 22349069

Group type: EXPERIMENTAL
Intervention: HTS 6%
Number of subjects: 40

Group type: COMPARATOR
Intervention: IS 0.9%
Number of subjects: 40
Study: 20622362

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (Cisplatinum 40 mg/m2 and 5 Fluorouracil 500 mg/m2 continuous infusions with radiotherapy on D2-D5 in first and last 5 sessions of radiation therapy)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both groups (Concurrent chemoradiation and Control)
Number of subjects: 102
Study: 18757458

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 14999109

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (0.5 to 1.0 g per square meter of body‐surface area) plus corticosteroids
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (500 to 3000 mg per day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Azathioprine (1 to 3 mg per kilogram of body weight per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cyclophosphamide (long-term therapy)
Number of subjects: 59
Study: 12372041

Group type: EXPERIMENTAL
Intervention: High dose tacrolimus (trough 12-17 ng/mL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low dose tacrolimus (trough 5-10 ng/mL)
Number of subjects: 28
Study: 9522106

Group type: EXPERIMENTAL
Intervention: System I (investigational testosterone transdermal system)
Number of subjects: 33

Group type: COMPARATOR
Intervention: System II (marketed testosterone transdermal system)
Number of subjects: 33

Group type: COMPARATOR
Intervention: System I vs System II
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 33
Study: 7652966

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1881

Group type: COMPARATOR
Intervention: No thrombolytic therapy (Control)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 1881
Study: 2540099

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory agents (NSAIA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated RA patients
Number of subjects: 20
Study: 352139

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chenodeoxycholic acid (CDC) and phenobarbital (PB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (calcified gallstones)
Number of subjects: 0
Study: 31967501

Group type: EXPERIMENTAL
Intervention: Deep Learning Reconstruction (DLR)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Iterative Reconstruction (IR)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Adaptive Iterative Dose Reduction (AIDR) 3D
Number of subjects: 59
Study: 30095550

Group type: EXPERIMENTAL
Intervention: Ketamine (0.4 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 100
Study: 29753000

Group type: EXPERIMENTAL
Intervention: Early postoperative ambulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no early ambulation)
Number of subjects: 120
Study: 26812997

Group type: EXPERIMENTAL
Intervention: Feedback labelled with the feedback provider's profession (two comments correctly labelled and two incorrectly labelled)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unlabelled feedback where participants guessed the provider's profession
Number of subjects: 45
Study: 24717713

Group type: EXPERIMENTAL
Intervention: Sealants/PRRs
Number of subjects: 534
Study: 23740915

Group type: EXPERIMENTAL
Intervention: VRS with instructor feedback (DSF)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: VRS without instructor feedback (DS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No VRS features (NDS)
Number of subjects: 43
Study: 20429800

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 17890456

Group type: EXPERIMENTAL
Intervention: BEACOPP regimen
Number of subjects: 38
Study: 16827813

Group type: EXPERIMENTAL
Intervention: R216073 (2,000 mg)
Number of subjects: 20
Study: 12783595

Group type: EXPERIMENTAL
Intervention: Natalizumab 3 mg/kg every 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab 6 mg/kg every 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab (both doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 0
Study: 10617734

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention emphasizing health risks of ETS for children
Number of subjects: 479

Group type: COMPARATOR
Intervention: Routine smoking cessation advice
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group receiving safety information
Number of subjects: 479
Study: 8751632

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 66
Study: 1400057

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 24

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: All groups (including ibuprofen, pentoxifylline, and control)
Number of subjects: 24
Study: 2867712

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study: 30840918

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (Synergy 1) 10 g for three months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for three months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (Synergy 1 and placebo)
Number of subjects: 34
Study: 30081962

Group type: EXPERIMENTAL
Intervention: Sinhala version of Menopause Rating Scale (MRS)
Number of subjects: 166
Study: 26690291

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: DETOX
Number of subjects: 95
Study: 25912670

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention (n = 22)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Delayed waitlist control condition (n = 17)
Number of subjects: 39
Study: 22492565

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help treatment (online)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Obese BED individuals
Number of subjects: 74
Study: 20817794

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily for 3 months (after initial atorvastatin or placebo)
Number of subjects: 40
Study: 18586995

Group type: EXPERIMENTAL
Intervention: Telephone-based referral care management (TBR-CM) intervention, which included usual care plus one or two brief motivational telephone sessions.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care, which consisted of scheduling a behavioral health care appointment followed by a letter and reminder by telephone.
Number of subjects: 113
Study: 15849531

Group type: EXPERIMENTAL
Intervention: Intensive monthly counseling sessions about condom use (8 sessions)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Follow-up after the trial
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Follow-up survey
Number of subjects: 966
Study: 12444179

Group type: EXPERIMENTAL
Intervention: Glycoprotein-D-subunit vaccine
Number of subjects: 2714

Group type: COMPARATOR
Intervention: Control injection
Number of subjects: 2714
Study: 10083699

Group type: EXPERIMENTAL
Intervention: Intensive dissemination method (mailout enhanced by personal contact with midwifery facilitators)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Simple dissemination method (mailout of the 'Fresh Start' program)
Number of subjects: 23
Study: 7552591

Group type: EXPERIMENTAL
Intervention: 50 mcg/kg loading dose of diamorphine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 200 mcg/kg loading dose of diamorphine
Number of subjects: 27
Study: 3065875

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg twice daily from the 12th day until onset of the following menstrual period
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 161
Study: 30305148

Group type: EXPERIMENTAL
Intervention: Psychological Support for Personality (PSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 28407415

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lixisenatide + Insulin glargine
Number of subjects: 28
Study: 25853384

Group type: EXPERIMENTAL
Intervention: Cervical administration of radiocolloid and blue dye (Group 1)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Subserosal injection of blue dye (Group 2)
Number of subjects: 188
Study: 23483175

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13479

Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 13479
Study: 21939798

Group type: EXPERIMENTAL
Intervention: Reamed nailing up to 12 mm with an 11 mm tibial nail (n: 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimally reamed nailing up to 10 mm with a 9 mm tibial nail (n: 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reamed nailing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimally reamed nailing
Number of subjects: 100
Study: 19127025

Group type: EXPERIMENTAL
Intervention: Glass fiber-reinforced composite resin (GFRCR) space maintainer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Band-and-loop space maintainer
Number of subjects: 30
Study: 20593635

Group type: EXPERIMENTAL
Intervention: Adjunctive Periochip (chlorhexidine) with scaling and root planing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 50
Study: 16139697

Group type: EXPERIMENTAL
Intervention: Traditional method (T)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Simplified method (S)
Number of subjects: 122
Study: 11901328

Group type: EXPERIMENTAL
Intervention: Wrist protector
Number of subjects: 721

Group type: COMPARATOR
Intervention: Control group (unprotected)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Wrist protector (per-protocol analysis)
Number of subjects: 721
Study: 9776411

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/day
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/alternate days
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 7531109

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice daily for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2904755

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean final daily dose 2.5 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nitrendipine (mean final daily dose 13.9 mg)
Number of subjects: 72
Study: 12189744

Group type: EXPERIMENTAL
Intervention: Permixon 320 mg per day
Number of subjects: 704

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg per day
Number of subjects: 704
Study: 29429427

Group type: EXPERIMENTAL
Intervention: Listening Visits (LV) delivered by nurses
Number of subjects: 0